Company - Our Story - Recordati
Our first 100 years
In the 19th century the Recordati family began a small pharmacy, in Correggio, Northern Italy, serving their local community. In 1926, Giovanni Recordati moves from experimenting in the back of that same pharmacy, to founding a company at 28 years old “Laboratorio Farmacologico Reggiano”.
One hundred years later, in 2026, we stand as a global pharmaceutical group with a presence in over 150 countries, committed to unlocking the full potential of life. Our centenary is not just a celebration of longevity—it is a confirmation of our purpose, values, continuity and care. As we mark this milestone, we honour the legacy of the people, patients and partners who shaped our journey, and embrace the responsibility of shaping the next hundred years.
When our company was born, Giovanni pioneered the production of medicines focused on chronic conditions – and within just two decades his small team grows to over 300 people. He sadly passed in 1952, before he could see his ambitious plans for expansion come to life, but his eldest son Arrigo and the generations thereafter, protected his legacy – and his dream lived on in the heart of his family, and the growing family in the Recordati company.
Recordati started by focussing on where help was needed most – common illnesses that affect large populations day-to-day. The illnesses right in front of us, where we knew more could be done to help – from heart conditions, mental illness to prostate cancer. But as the world has grown around us, so has the need.
With the huge benefits of medical innovation, come discoveries of rare, devastating conditions, where for some, no treatment exists at all – with 7,000 known rare diseases, less than 10% have an available treatment option. So, since 2007, Recordati has also focused on helping the few who suffer from little known conditions such as Cushing’s disease, acromegaly, porphyria to rare cancers like high-risk neuroblastoma.
Today, 100 years and three generations later, Giovanni’s focus and determination lives on. His company, Recordati, is now a global pharmaceutical group, listed on the Italian stock exchange, with around 4,580 employees.
Developing and making medicines are still at our core, with two chemical plants and seven manufacturing sites worldwide, and a focus to continuously develop new specialties, new treatments, and invest in medical innovations that bring a brighter future.
Every day, in every way, we do everything possible so that people can live full lives – we do this together, working closely with suppliers, partners and doctors from Brazil to the Far East, in around 150 countries. We will always continue to build with our people, planet, community, and our own roots, at our heart.
The future is where our purpose comes alive. 100 years behind us. Infinite possibilities ahead.
The next century has not yet been written. But its clear our purpose will remain: Unlocking the full potential of life.
MILESTONES
2023
- Agreement with GSK to commercialize Avodart® (dutasteride) and Combodart®/Duodart®
2024
- Agreement with Sanofi to acquire the global rights to Enjaymo®, strengthening its rare diseases franchise
2025
- License and supply agreement with Amarin to commercialise Vazkepa® strengthening its cardiovascular franchise
1926
Giovanni Recordati founds the Laboratorio Farmacologico Reggiano in Correggio (RE, Italy)
1953
Transfer of headquarters to Milan
1961
Recordati – Syntex (now part of Roche) licence agreement. Located in Silicon Valley, Syntex was a pioneering company in the study and synthesis of steroid hormones
1963
Inauguration of the pharmaceutical chemical plant in Campoverde di Aprilia
1984
Listing on the Italian Stock Exchange
1995
Beginning the process of internationalisation – Establishment of a subsidiary in Spain, now called Casen Recordati
1999
Acquisition of Doms Adrian (France)
2000
Acquisition of Bouchara (France)
2001
Establishment of Bouchara Recordati in France
2005
- Acquisition of Merckle Recordati in Germany, now Recordati Pharma
- Establishment of Recordati Pharmaceuticals in the United Kingdom
- Establishment of Recordati Hellas in Greece
- Establishment of the new pharmaceutical chemical plant in Cork, Ireland
2006
Acquisition of the Grupo Jaba companies in Portugal, today Jaba Recordati
2007
Entry to the rare diseases sector with the acquisition of Orphan Europe, now Recordati Rare Diseases
2008
- Acquisition of FIC and FIC Médical, dedicated to the registration and promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries
- Acquisition of Yeni Ilaç in Türkiye
2009
Acquisition of Herbacos-Bofarma in the Czech Republic and Slovakia, today Herbacos Recordati
2010
Acquisition of ArtMed International in Romania, now Recordati Romania
2011
Acquisition of Dr. F. Frik Ilaç in Turkey, now Recordati Ilaç
2012
- Entry into the US market rare diseases sector
- Acquisition of product portfolio for the treatment of a number of rare diseases in the US
- Acquisition of Farma-Projekt in Poland, now Recordati Polska
2013
- Acquisition of Opalia Pharma and its cGMP certified production facilities in Tunisia, now Opalia Recordati
- Acquisition of Laboratorios Casen Fleet and its cGMP certified production facilities in Spain, now Casen Recordati
2015
Establishment of new subsidiaries in Brazil, Mexico and Colombia
2016
- SPC and OTC portfolio strengthened
- Acquisition of Italchimici in Italy
- Acquisition of Pro Farma AG, now Recordati AG, in Switzerland and Austria
2017
- Acquisition of Natural Point in Italy
- Acquisition of Tonipharm in France
- Establishment of new subsidiaries in Japan and Australia
2019
- Expansion of the rare diseases product portfolio: entry into the endocrinology sector
- Establishment of Recordati Bulgaria
2022
- Acquisition of EUSA Pharma (UK) Ltd, a global specialist pharmaceutical company focused on rare diseases and niche oncology
2023
- Agreement with GSK to commercialize Avodart® (dutasteride) and Combodart®/Duodart®
2024
- Agreement with Sanofi to acquire the global rights to Enjaymo®, strengthening its rare diseases franchise
2025
- License and supply agreement with Amarin to commercialise Vazkepa® strengthening its cardiovascular franchise